Kyras Therapeutics Obtains Series A Funding

  • Feed Type
  • Date
    12/14/2015
  • Company Name
    Kyras Therapeutics
  • Mailing Address
    54 West 21st Street New York, NY 10010 USA
  • Company Description
    Kyras is a biopharmaceutical company developing drugs that address currently incurable cancers and developmental disorders caused by RAS gene mutations. We are a team of experienced scientists, drug developers, and entrepreneurs dedicated to advancing novel medicines to improve patients’ lives.
  • Website
    http://www.kyrasrx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    Undisclosed
  • Transaction Round
    Series A
  • Proceeds Purposes
    The company will use the funds to develop the RAS family of proteins.
  • M&A Terms
  • Venture Investor
    Versant Ventures
  • Venture Investor
    Investor
  • Venture Investor
    Investor

Trending on Xconomy